|

Disitamab Vedotin Injection Clinical Trials

3 actively recruiting trials

Also known as: DV,RC48, DV,RC48-ADC

Pipeline

Phase 2: 2Phase 2/3: 1

Top Sponsors

  • RemeGen Co., Ltd.3

Indications

  • Cancer3
  • Castration-resistant Prostate Cancer1
  • Gastroesophageal Junction Adenocarcinoma1
  • Gastric Cancer1
  • Breast Cancer1

Other3 trials

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Phase 2/3
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Phase 2
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.